Egle Identifies First Novel Regulatory T-cell Targets Under its Collaboration with Takeda
Shots: Alphamab to receive upfront, milestones and royalties on sales of KN035 (ASC22). Ascletis to get exclusive development and commercialization rights for Alphamab’s KN035 (ASC22) in Greater China Alphamab will be responsible to manufacture and commercialize ASC22 (KN035) in Greater China and Ascletis to receive economics (Ex-China) from Alphamab on its regulatory approval in China […]Read More
